Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Ver. Summary Created by Modification Content Size Created at Operation
1 -- 3292 2023-07-24 11:50:48 |
2 Reference format revised. Meta information modification 3292 2023-07-25 02:34:28 |

Video Upload Options

Do you have a full video?


Are you sure to Delete?
If you have any further questions, please contact Encyclopedia Editorial Office.
Mercola, J.; D’Adamo, C.R. Associations of Linoleic Acid Intake and Chronic Disease. Encyclopedia. Available online: (accessed on 29 November 2023).
Mercola J, D’Adamo CR. Associations of Linoleic Acid Intake and Chronic Disease. Encyclopedia. Available at: Accessed November 29, 2023.
Mercola, Joseph, Christopher R. D’Adamo. "Associations of Linoleic Acid Intake and Chronic Disease" Encyclopedia, (accessed November 29, 2023).
Mercola, J., & D’Adamo, C.R.(2023, July 24). Associations of Linoleic Acid Intake and Chronic Disease. In Encyclopedia.
Mercola, Joseph and Christopher R. D’Adamo. "Associations of Linoleic Acid Intake and Chronic Disease." Encyclopedia. Web. 24 July, 2023.
Associations of Linoleic Acid Intake and Chronic Disease

The intake of linoleic acid (LA) has increased dramatically in the standard American diet. LA is generally promoted as supporting human health, but there exists controversy regarding whether the amount of LA currently consumed in the standard American diet supports human health. While LA is considered to be an essential fatty acid and support health when consumed in modest amounts, an excessive intake of LA leads to the formation of oxidized linoleic acid metabolites (OXLAMs), impairments in mitochondrial function through suboptimal cardiolipin composition, and likely contributes to many chronic diseases that became an epidemic in the 20th century, and whose prevalence continues to increase. As LA consumption increases, the potential for OXLAM formation also increases. OXLAMs have been associated with various illnesses, including cardiovascular disease, cancer, and Alzheimer’s disease, among others. Lowering dietary LA intake can help reduce the production and accumulation of OXLAMs implicated in chronic diseases. 

linoleic acid (LA) seed oils cardiolipin oxidized linoleic acid metabolites (OXLAMs) 4-hydroxynonenal (HNE) omega-3 omega-6

1. Introduction

Polyunsaturated fatty acids (PUFAs) are basic components involved in the architecture and function of cellular membranes and play key roles in several biological processes. PUFAs are endogenous mediators for cell signaling and are involved in the regulation of gene expression. They are also metabolic precursors of eicosanoids, such as prostaglandins and leukotrienes, and docosanoids, such as protectins or resolvins [1].
The most common source of PUFAs in the human diet today are vegetable and seed oils that contain linoleic acid (LA), which is an omega-6 fatty acid. LA is a major constituent of human tissues [2], and it is considered to be an essential fatty acid. Deficiencies in essential fatty acid intake among adults have been documented for decades. [3][4] Furthermore, the important effects of LA in animal and human physiology have been studied for decades [5][6][7][8][9], and a modest, evolutionarily consistent intake of LA has been associated with a decreased risk of atherosclerosis [10], hypercholesterolemia [11][12], headaches when combined with omega-3 fatty acid supplementation [13], and other chronic health conditions.
However, when the levels of LA become highly elevated in the blood through dietary intake in amounts that far exceed recommended amounts, this PUFA becomes a precursor to oxidized LA metabolites (OXLAMs), such as 4-Hydroxynonenal (HNE), 9- and 13-hydroxy-octadecadienoic acid (9- and 13-HODE), and 9- and 13-oxo-octadecadienoic acid (9- and 13-oxoODE).
Furthermore, LA conversion may lead to the formation of free radicals, such as 8-hydroxyoctanoic acid and heptanoic acid [14]. In addition, in some instances, LA may be further metabolized into arachidonic acid (AA), which is a precursor to oxidized AA metabolites (OXAAMs), including 5-, 8-, 9-, 11-, 12-, and 15-hydroxy-eicosatetraenoic acid (HETE) [15]. The increased circulation of oxidized metabolites and free radicals has been linked to different types of diseases (e.g., cardiovascular, atherosclerotic, hepatic, etc.) [16].

2. How Much LA Is Required in the Human Diet?

The first demonstration of the essential requirement for LA in animal diets was obtained by Burr and Burr in 1929–1930 [13]. They showed that rats receiving 0.6% of their total dietary calories as LA were 30% higher in body weight compared to total-fat-deficient rats and did not develop skin desquamation and tail necrosis [17][18][19].
This led to the establishment of the requirement of 1% of the total daily calories being omega-6 fat, which was later extended to 2% of the total daily calorie intake in humans to ensure sufficiency. This was confirmed by two studies where the physiological symptoms of omega-6 deficiency in human infants, as established by scaling of the skin, were abolished [20].
However, a careful review of the data used to establish LA being essential to the diet found that this conclusion was established using control diets that were not only deficient in omega-6 fatty acids, but also omega-3 fatty acids. This dual deficiency in the control diets seemed to invalidate the establishment of an omega-6 fatty acid requirement from these data [21].
Subsequent studies in rat models similar to those used to originally classify LA as an essential fatty acid have demonstrated that the dietary omega-3 fatty acid, alpha-linolenic acid (ALA), is able to diminish the symptoms of LA deficiency [22]. This strongly suggests that the absence of ALA in the original studies probably heightened the significance of the physiological symptoms caused by LA deficiency. It seems that, at least for the rat model, the nutritional requirement for LA has probably been seriously overestimated. A more precise estimation of the LA requirement is likely closer to a 75% reduction, or 0.5%, of the dietary energy rather than 2% [23].

3. The Omega 3:6 Ratio

Among the many types of omega-3 fatty acids, the three most important are eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), which are “long-chain” omega-3 fatty acids, and alpha linoleic acid (ALA)—a “short-chain” omega-3 fatty acid. The human body is unable to produce essential fatty acids endogenously.
Therefore, omega-3 fatty acids must be consumed regularly through the diet. Animal foods such as cold-water fish are ideal sources of EPA and DHA, while ALA is mainly derived from plants. EPA and DHA have anti-inflammatory effects and ALA must be converted to EPH and DHA. This conversion is an inefficient process, particularly in men, with less than 20% being converted [24]. Therefore, special attention should be paid to obtaining EPA and DHA through diet or supplementation.
The benefits of maintaining the proper omega 3:6 ratio are well-established. Bodily tissues consist primarily of saturated and monounsaturated fats, which are a readily utilized source of nutrients that support the development and maintenance of cells [25]. The primary dietary PUFAs are omega-3 and omega-6 fats, which the body needs in relatively small quantities.
It is important to consume sufficient amounts of omega-3 fatty acids to sustain optimal health, with the recommended daily serving being between 500 and 1000 milligrams of omega-3 fatty acids [26][27]. Contrary to previous perceptions, however, consuming larger servings of omega-3 fatty acids does not support an ideal ratio. Instead, excessive quantities of omega-3s may cause additional metabolic damage—similar to that which occurs due to the conversion of elevated LA levels.

4. Pathophysiological Mechanism of Elevated LA Levels

As revealed in Figure 1, the primary reason why excess LA in the body leads to cellular tissue damage is because this highly fragile PUFA is easily altered through oxidation. Like other types of PUFAs, LA consists of fragile double bonds that are susceptible to oxidative damage [28].
Figure 1. Mechanism of oxidative stress generated through oxidation of polyunsaturated fats.
The double bonds are the key to understanding why PUFAs are highly perishable and prone to oxidation. LA is metabolized in a multistep pathway to arachidonic acid (AA) through the conversion to gamma-linolenic acid (GLA) due to Δ6desaturase enzyme, which varies based on the activity of desaturase enzymes. GLA is converted to dihomo-γ-linolenic acid (DGLA), which is the immediate precursor to AA. Chronically elevated levels of AA can contribute to a state of chronic inflammation and have been associated with autoimmunity [29]. This has led to some popular debate regarding the influence of LA intake on AA levels, with some recent papers suggesting that an excessive LA intake can lead to the accumulation of AA-derived pronociceptive lipid mediators and a reduction in antinociceptive lipid mediators obtained from omega-3 fatty acids [30][31]. However, a systematic review found that LA intake was not associated with tissue concentrations of AA in human beings [32]. Thus, the conversion of LA to AA is unlikely to be a concern to human beings at modest levels of consumption.

4.1. How Excess LA Consumption Alters Health

As noted previously, the conversion of LA to AA is unlikely to play a major role in the pathology related to excessive LA intake. LA’s well-documented propensity to enhance lipid peroxidation and the formation of oxidized LA-derived lipid metabolites (OXLAMs) is more likely to contribute significantly to its detrimental effects.
Lipid peroxidation is a well-established process associated with various chronic diseases. Excessive iron, for example, contributes to this damage through a process called ferroptosis, characterized by the accumulation of iron-dependent lipid peroxides that cause membrane injury and cell death. This mechanism plays a significant role in the development of cancer cardiovascular diseases, neurodegeneration and aging.
Membrane lipids containing PUFAs, such as LA, are particularly susceptible to peroxidation due to the weak C-H bonds between adjacent C=C double bonds. During lipid peroxidation, primary products such as lipid hydroperoxides are formed, which can further oxidize to produce reactive aldehydes, with 4-hydroxynonenal (4-HNE) being the most extensively studied and biologically relevant product of LA peroxidation. The accumulation of peroxidized lipids, including 4-HNE, can influence cellular processes, ranging from proliferation to apoptosis and necrosis, depending on their concentration.
4-hydroxynonenal (4-HNE) is an extraordinarily reactive compound and one of the most studied and seemingly biologically relevant products of lipid peroxidation, and is a product of LA peroxidation. Peroxidized lipids are bioactive. They can have effects on cells similar to those of hydrogen peroxide: low levels can stimulate proliferation; higher levels block proliferation and yet higher ones induce apoptosis and necrosis. 4-HNE tends to concentrate in biomembranes rather than in the aqueous space of cells.
When one has elevated tissue levels of LA, consuming an excess of LA, even from unprocessed whole foods, can accelerate metabolic damage. This is due to the propensity for LA to be converted to OXLAMs or OXAAMs that can damage structures, including DNA, mitochondria, cell membranes, proteins, and stem cells [33][34][35].

4.2. LA Remains in Tissues for Extended Time Periods

Another major reason why seed oils are pernicious to overall health is that they remain in the body for extended periods. The half-life of LA is approximately 680 days, or approximately two years [36]. This means that it takes approximately six years to replace 95% of the LA in the body with healthy fats—making this a primary reason to maintain low LA intake. Omega-3 fatty acids, such as DHA and EPA, have half-lives of 2.5 years and a few months, respectively [37][38]. The body also converts certain amounts of DHA to EPA.

4.3. Cardiolipin: Stealth Fat in Mitochondria

Mitochondria are subcellular organelles that are responsible for producing most of the body’s cellular energy in the form of adenosine triphosphate (ATP) [39]. It is the presence of mitochondria that distinguishes mammals (e.g., humans) from bacteria and allow life to be multicellular.
These organelles produce approximately 85% of the energy for the body through the generation of ATP during oxidative phosphorylation. If mitochondrial dysfunction develops, physical symptoms (e.g., chronic fatigue) may arise, along with an increased susceptibility to disease. It is vital to take preventive measures to improve and maintain mitochondrial health as it profoundly impacts longevity. Cardiolipin optimization reinforces enhanced mitochondria activity and energy production.
To emphasize the importance of this phospholipid, 20% of the fat in the mitochondria is found in the form of cardiolipin [40]. The human body has over 100,000 trillion mitochondria, and mitochondrial health is largely dependent upon the type of dietary fats that are available for cardiolipin synthesis within these specialized organelles.
Cardiolipin is composed of four fatty acids [41], unlike triglycerides, which have three fatty acids, but the individual fats that comprise cardiolipin vary widely. Examples include LA, palmitic acid, and the fatty acids found in fish oil, such as DHA and EPA. Cardiolipin is synthesized from fatty acids that are consumed through the diet; thus, the overconsumption of LA in the form of seed oils can alter the formation of the inner mitochondrial membrane, cristae, and complex IV.
Cardiolipin molecules containing one or more LA fatty acids are highly susceptible to free-radical-induced lipid peroxidation. The oxidation of cardiolipin is involved in regulating apoptosis, mitophagy, and other cellular functions. Interestingly, LA-containing cardiolipin is preferentially oxidized over other phospholipids in the inner mitochondrial membrane, even in the presence of more-oxidizable fatty acids such as arachidonic acid.
This is important, because mitochondrial lipids are necessary for maintaining the structural integrity and proper functioning of mitochondria. Cardiolipin is prone to free-radical-induced lipid peroxidation due to the presence of up to four chains of LA. The oxidation of cardiolipin plays an important role in the regulation of apoptosis, mitophagy, and other cellular functions.
The oxidation of cardiolipin plays an important role in the regulation of apoptosis, mitophagy, and other cellular functions. LA-containing cardiolipin is preferentially oxidized over other phospholipids that are found in the inner mitochondrial membrane, including phosphatidylinositol, phosphatidylserine, phosphatidylinositol, and phosphatidylethanolamine. This occurs even in the presence of more oxidizable fatty acids, such as arachidonic acid.
Emerging evidence suggests that mitochondrial lipid peroxidation not only affects the structural integrity of mitochondria, but also mitochondrial functions, such as protein transportation, respiratory metabolism for ATP generation, mitochondrial dynamics and quality control through the fission and fusion of mitochondria, and mitophagy.
Mitochondrial proteins, which constitute a significant portion of proteins within the inner mitochondrial membrane, are highly susceptible to modification by 4-HNE. Approximately thirty percent of all proteins modified by 4-HNE are mitochondrial proteins. Consequently, endogenously produced 4-HNE resulting from oxidative stress has been shown to cause mitochondrial dysfunction in various cell types and organs during both physiological and pathological conditions. This vulnerability of mitochondrial proteins to 4-HNE modification contributes to their critical role in the development of mitochondrial dysfunction.

5. Associations between LA Intake and Chronic Disease

Oxidative stress, tissue damage, and mitochondrial dysfunction from excess LA is not only responsible for cardiovascular disease and Alzheimer’s onset, but additional chronic diseases, including cancer, dementia, obesity, and diabetes are also associated with oxidized metabolites. There is conflicting evidence on the associations between LA intake and many of these chronic diseases, which are summarized below in Table 1.
Table 1. Summary of health effects of linoleic acid.
While the evidence is still conflicting in some instances, the mechanisms underlying excessive LA intake are reflected in a wide variety of chronic diseases. A recent study [53] found that high-fat diets increased the formation of vitamin A degradation products, known as bisretinoids, in ocular tissues. These degradation products are known to cause damage to the retina directly, but they also participate in the formation of lipofuscin in the retina. Lipofuscin is a byproduct of PUFA peroxidation. The study found the PUFA linoleic acid to be a causal factor of eye damage.
Soy oil is by far the most widely produced and consumed seed oil in the US. Using mice, researchers in 2020 found that a high soybean oil diet not only led to obesity and diabetes, but could also affect neurological conditions such as autism, Alzheimer’s disease, anxiety, and depression [54]. The same research team found in 2015 [55] that soy oil induced obesity, diabetes, insulin resistance, and fatty liver in mice. Then, in a 2017 study [56], the same group learned that if soy oil was engineered to be low in LA, it induced less obesity and insulin resistance.
Type I diabetes is an autoimmune condition. The beta-cells of the pancreas are attacked by antibodies from the immune system, over time leading to their destruction and the inability to produce insulin. One study [57] found that the reason for antibody production was the overexpression of the enzyme 12/15-lipoxygenase, which is an enzyme involved not only in synthesizing inflammatory leukotrienes, but also metastatic cancer.
Leukotrienes are PUFA metabolites and are responsible for the development of type I diabetes. This suggests that a 12/15-LOX inhibitor would be therapeutic. This study administered a leukotriene inhibitor and found it effective in preventing the development of beta-cell autoimmunity. A more fundamental approach would be to avoid or replace the source of leukotrienes, which would be dietary PUFAs.

6. Dietary Sources of LA and Mitigation Strategies

In general, the lowest LA-containing source of fats would be the preferred fats of choice for lowering the LA burden in the diet. Olive oil is a popular cooking oil that is prominently featured in Mediterranean diets, which generally contain far fewer seed oils considering the abundant use of olive oil. 

However, olive oil demonstrated a nearly 10-fold wide variability in the percentage of LA and the vast majority of commercial olive oil, and avocado oils, are adulterated with seed oils. A recent study evaluated 89 olive cultivars and found a range of 3% to 27% levels of LA [58]. Tests have also revealed that anywhere from 60 to 90% of the olive oils sold in American grocery stores and restaurants are adulterated with cheap, oxidized, omega-6 vegetable oils, such as sunflower oil or peanut oil, or nonhuman-grade olive oils, which are harmful to health in a number of ways [59].
Although this problem is concerning, instead of avoiding all cooking oils (e.g., vegetable and seed oil), healthier choices include those that have been used for centuries, such as butter and beef tallow. In addition to containing the lowest LA content, these sources of fats also provide the fat-soluble vitamins A, D, and K2.
Despite these sources being readily available, most Americans simply fail to obtain enough preformed vitamin A in their diet. This can contribute to many chronic diseases, including cardiovascular disease [60] and cancers [61]. An elevated seed oil intake also adversely impacts health, survival, and vision [62]. Coconut oil is also very low in LA but does not have the essential fat-soluble vitamins that tallow and butter contain.

6.1. Sources of Animal Protein and Varying LA Contents

Animals are typically fed corn, soy, or other seeds and grains, which is radically different from their native, traditional, or ancestral diet. This presents a problem for nonruminant animals due to the concentration of LA in the seeds and grains they are fed. Ruminants are animals with multiple parts to their stomachs. This includes cows, buffalo, sheep, lamb, goats, deer, elk, and many other game animals.
Ruminants have low LA in both their meat and milk, no matter what they eat [63]. This is because their stomach has a ‘biohydrogenation chamber’ that contains bacteria that can convert the high LA fat they eat from grains and seeds into saturated and monounsaturated fats. This is in contrast to animals with one stomach, such as chickens and pigs, that when fed a diet high in LA, including corn and soy, experience an increase in high levels of LA in their tissues, similar to the process that has been observed in humans [64].
The ability of the biohydrogenation chamber to efficiently convert high LA fat to saturated and monounsaturated fats is well known, as the difference in LA in ruminants that are 100% grass-fed and those that are fed corn and soy is only approximately 0.5%. This is why, from an LA intake perspective, there is not much difference between concentrated animal feeding operation (CAFO) beef and grass-fed-only beef. However, grass-fed beef is preferred, as it contains less glyphosate, other toxins, and hormones.

6.2. Carnosine Helps Lower Oxidative Damage from LA

Carnosine is an endogenously produced dipeptide, and it consists of only two amino acids, beta-alanine and histidine [65]. It is a potent antioxidant that helps limit the damage from excess LA by binding to ALEs. It serves as a sacrificial sink for reactive oxygen species (ROS) and ALEs [66] by letting these damaging molecules destroy it rather than mitochondria, DNA, or proteins, as depicted in Figure 2.
Figure 2. Carnosine scavenges ROS and ALES such as 4-HNE generated through the oxidation of fatty acid cell membranes during oxidative stress.
The highest concentrations of carnosine are found in the muscles and brain [67]. Carnosine is also found in meats but is not contained in any plant foods. That is why individuals following a vegetarian or vegan diet typically have lower levels of carnosine in their muscles. This is also one reason why many strict vegans who do not properly compensate for low carnosine intake from meat and other nutritional deficiencies may experience difficulties building muscle.


  1. Chapkin, R.S.; McMurray, D.N.; Davidson, L.A.; Patil, B.S.; Fan, Y.Y.; Lupton, J.R. Bioactive dietary long-chain fatty acids: Emerging mechanisms of action. Br. J. Nutr. 2008, 100, 1152–1157.
  2. Ramsden, C.E.; Ringel, A.; Feldstein, A.E.; Taha, A.Y.; MacIntosh, B.A.; Hibbeln, J.R.; Majchrzak-Hong, S.F.; Faurot, K.R.; Rapoport, S.I.; Cheon, Y.; et al. Lowering dietary linoleic acid reduces bioactive oxidized linoleic acid metabolites in humans. Prostaglandins Leukot. Essent. Fat. Acids 2012, 87, 135–141.
  3. Holman, R.T.; Johnson, S.B.; Kokmen, E. Deficiency of essential fatty acids and membrane fluidity during pregnancy and lactation. Proc. Natl. Acad. Sci. USA 1968, 61, 1053–1059.
  4. Behrman, R.E.; Reller, L.B.; Carey, H.V. Essential fatty acid deficiency in a patient receiving prolonged intra-venous alimentation. N. Engl. J. Med. 1971, 285, 19–21.
  5. Klein, P.D.; Johnson, R.M. Phosphorous metabolism in unsaturated fatty acid-deficient rats. J. Biol. Chem. 1954, 211, 103–110.
  6. Hayashida, T.; Portman, O.W. Swelling of liver mitochondria from rats fed diets deficient in essential fatty acids. Proc. Soc. Exp. Biol. Med. 1960, 103, 656–659.
  7. Cornwell, D.G.; Panganamala, R.V. Atherosclerosis an intracellular deficiency in essential fatty acids. Prog. Lipid Res. 1981, 20, 365–376.
  8. Smith, E.B. The effects of age and of early atheromata on the intimal lipids in men. Biochem. J. 1962, 84, 49.
  9. Smith, E.B. Lipids carried by S1 0–12 lipoprotein in normal and hypercholesterolaemic serum. Lancet 1962, 2, 530–534.
  10. Das, U.N. Bioactive lipids and vascular disease. Eur. J. Clin. Nutr. 2021, 75, 1528–1531.
  11. Salem, N.; Wegher, B.; Mena, P.; Uauy, R. Arachidonic and docosahexaenoic acids are biosynthesized from their 18-carbon precursors in human infants. Proc. Natl. Acad. Sci. USA 1996, 93, 49–54.
  12. Ramsden, C.E.; Zamora, D.; Faurot, K.R.; MacIntosh, B.; Horowitz, M.; Keyes, G.S.; Yuan, Z.X.; Miller, V.; Lynch, C.; Honvoh, G.; et al. Dietary alteration of n-3 and n-6 fatty acids for headache reduction in adults with migraine: Randomized controlled trial. BMJ 2021, 374, n1448.
  13. Burr, G.O.; Burr, M.M. A new deficiency disease produced by the rigid exclusion of fat from the diet. J. Biol. Chem. 1929, 82, 345–367.
  14. Suzuki, N.; Sawada, K.; Takahashi, I.; Matsuda, M.; Fukui, D.; Tokuyasu, H.; Shimizu, H.; Yokoyama, J.; Akaike, A. Association between polyunsaturated fatty acid and reactive oxygen species production of neutrophils in the general population. Nutrients 2020, 12, 3222.
  15. Santoro, N.; Caprio, S.; Giannini, C.; Kim, G.; Kursawe, R.; Pierpont, B.; Shaw, M.M.; Feldstein, A.E. Oxidized fatty acids: A potential pathogenic link between fatty liver and type-2 diabetes in obese adolescents. Antioxid. Redox Signal. 2014, 20, 383–389.
  16. Pizzino, G.; Irrera, N.; Cucinotta, M.; Pallio, G.; Mannino, F.; Arcoraci, V.; Squadrito, F.; Altavilla, D.; Bitto, A. Oxidative stress: Harms and benefits for human health. Oxid. Med. Cell. Longev. 2017, 2017, 8416763.
  17. Osborne, T.; Mendel, L.B. Growth on diets poor in true fats. JBC 1920, 45, 145–152.
  18. Spector, A.A.; Kim, H.Y. Discovery of fatty acids. J. Lipid. Res. 2015, 56, 11–21.
  19. Hansen, A.E. Essential fatty acids and infant nutrition; Borden award address. Pediatrics 1958, 21, 494–501.
  20. Hansen, A.E.; Wiese, H.F.; Boelsche, A.N. Role of linoleic acid in infant nutrition study Clinical and Chemical Study of 428 Infants Fed on Milk Mixtures Varying in Kind and Amount of Fat. Pediatrics 1963, 31, 171–192.
  21. Cunnane, S.C.; Guesnet, P. Linoleic acid recommendations—A house of cards. Prostaglandins Leukot. Essent Fat. Acids 2011, 85, 399–402.
  22. Igarashi, M.; Gao, F.; Kim, H.W.; Ma, K.; Bell, J.M.; Rapoport., S.I. Dietary n-6 PUFA deprivation for 15 weeks reduces arachidonic acid concentrations while increasing n-3 PUFA concentrations in organs of post-weaning male rats. Biochim. Biophys. Acta 2009, 1791, 132–139.
  23. Guesnet, P.; Lallemand, S.M.; Alessandri, J.M.; Jouin, M.; Cunnane, S.C. α-Linolenate reduces the dietary requirement for linoleate in the growing rat. Prostaglandins Leukot. Essent Fat. Acids 2011, 85, 353–360.
  24. Stark, A.H.; Crawford, M.A.; Reifen, R. Update on alpha-linolenic acid. Nutr. Rev. 2008, 66, 326–333.
  25. DiNicolantonio, J.J.; O’Keefe, J.H. Monosaturated fat vs. saturated fat: Effects on cardio-metabolic health and obesity. Mo. Med. 2022, 119, 69–73.
  26. Vannice, G.; Rasmussen, H. Position of the Academy of Nutrition and Dietetics: Dietary fatty acids for healthy adults. J. Acad. Nutr. Diet. 2014, 114, 136–153.
  27. Kris-Etherton, P.M. Fish consumption, fish oil, omega-3 Fatty Acids, and cardiovascular disease. Circulation 2002, 106, 2747–2757.
  28. Ayala, A.; Muñoz, M.F.; Argüelles, S. Lipid peroxidation: Production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid. Med. Cell. Longev. 2014, 2014, 360438.
  29. Hoxha, M.; Spahiu, E.; Prendi, E.; Zappacosta, B. A Systematic Review on the Role of Arachidonic Acid Pathway in Multiple Sclerosis. CNS Neurol. Disord. Drug Targets 2022, 21, 160–187.
  30. Birkic, N.; Azar, T.; Maddipati, K.R.; Minic, Z.; Reynolds, C.A. Excessive dietary linoleic acid promotes plasma accumulation of pronociceptive fatty acyl lipid mediators. Sci. Rep. 2022, 12, 17832.
  31. Singh, P.N.; Arthur, K.N.; Orlich, M.J.; James, W.; Purty, A.; Job, J.S.; Rajaram, S.; Sabaté, J. Global epidemiology of obesity, vegetarian dietary patterns, and noncommunicable disease in Asian Indians. Am. J. Clin. Nutr. 2014, 100, 359S–364S.
  32. Rett, B.S.; Whelan, J. Increasing dietary linoleic acid does not increase tissue arachidonic acid content in adults consuming Western-type diets: A systematic review. Nutr. Metab. 2011, 8, 36.
  33. Yoshida, Y.; Yoshikawa, A.; Kinumi, T.; Ogawa, Y.; Saito, Y.; Ohara, K.; Yamamoto, H.; Imai, Y.; Niki, E. Hydroxyoctadecadienoic acid and oxidatively modified peroxiredoxins in the blood of Alzheimer’s disease patients and their potential as biomarkers. Neurobiol. Aging 2009, 30, 174–185.
  34. Poirier, B.; Michel, O.; Bazin, R.; Bariéty, J.; Chevalier, J.; Myara, I. Conjugated dienes: A critical trait of lipoprotein oxidizability in renal fibrosis. Nephrol. Dial. Transplant. 2001, 16, 1598–1606.
  35. Esterbauer, H.; Gebicki, J.; Puhl, H.; Jürgens, G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radical Biol. Med. 1992, 13, 341–390.
  36. Dayton, S.; Hashimoto, S.; Dixon, W.; Pearce, M.L. Composition of lipids in human serum and adipose tissue during prolonged feeding of a diet high in unsaturated fat. J. Lipid. Res. 1966, 7, 103–111.
  37. Umhau, J.C.; Zhou, W.; Carson, R.E.; Rapoport, S.I.; Polozova, A.; Demar, J.; Hussein, N.; Bhattacharjee, A.K.; Ma, K.; Esposito, G.; et al. Imaging incorporation of circulating docosahexaenoic acid into the human brain using positron emission tomography. J. Lipid. Res. 2009, 50, 1259–1268.
  38. Braeckman, R.A.; Stirtan, W.; Soni, P.N. Pharmacokinetics of eicosapentaenoic acid in plasma and red blood cells after multiple oral dosing with icosapent ethyl in healthy subjects. Clin. Pharmacol. Drug Dev. 2014, 3, 101–108.
  39. Bertram, R.; Pedersen, M.G.; Luciani, D.S.; Sherman, A. A simplified model for mitochondrial ATP production. J. Theor. Biol. 2006, 243, 575–586.
  40. Ahmadpour, S.T.; Maheo, K.; Servais, S.; Brisson, L.; Dumas, J.F. Cardiolipin, the mitochondrial signature lipid: Implication in cancer. Int. J. Mol. Sci. 2020, 21, 8031.
  41. Dudek, J. Role of cardiolipin in mitochondrial signaling pathways. Front. Cell. Dev. Biol. 2017, 5, 90.
  42. Marangoni, F.; Agostoni, C.; Borghi, C.; Catapano, A.L. Dietary linoleic acid and human health: Focus on cardiovascular and cardiometabolic effects. Atherosclerosis 2020, 292, 90–98.
  43. Bu, T.; Tang, D.; Liu, Y.; Chen, D. Trends in Dietary Patterns and Diet-related Behaviors in China. Am. J. Health Behav. 2021, 45, 371–383.
  44. Zock, P.L.; Katan, M.B. Linoleic acid intake and cancer risk: A review and meta-analysis. Am. J. Clin. Nutr. 1998, 68, 142–153.
  45. Jaganjac, M.; Zarkovic, N. Lipid Peroxidation Linking Diabetes and Cancer: The Importance of 4-Hydroxynonenal. Antioxid. Redox Signal. 2022, 37, 1222–1233.
  46. Panov, A.V.; Dikalov, S.I. Cardiolipin, Perhydroxyl Radicals, and Lipid Peroxidation in Mitochondrial Dysfunctions and Aging. Oxidative Med. Cell. Longev. 2020, 2020, 1323028.
  47. Kim, J.; Minkler, P.E.; Salomon, R.G.; Anderson, V.E.; Hoppel, C.L. Cardiolipin: Characterization of distinct oxidized molecular species. J. Lipid Res. 2011, 52, 125–135.
  48. Kuschner, C.E.; Choi, J.; Yin, T.; Shinozaki, K.; Becker, L.B.; Lampe, J.W.; Kim, J. Comparing phospholipid profiles of mitochondria and whole tissue: Higher PUFA content in mitochondria is driven by increased phosphatidylcholine unsaturation. J. Chromatogr. B 2018, 1093–1094, 147–157.
  49. Belury, M.A.; Cole, R.M.; Snoke, D.B.; Banh, T.; Angelotti, A. Linoleic acid, glycemic control and Type 2 diabetes. Prostaglandins Leukot. Essent. Fat. Acids 2018, 132, 30–33.
  50. Naughton, S.S.; Mathai, M.L.; Hryciw, D.H.; McAinch, A.J. Linoleic acid and the pathogenesis of obesity. Prostaglandins Other Lipid Mediat. 2016, 125, 90–99.
  51. DiNicolantonio, J.J.; O’Keefe, J.H. Good Fats versus Bad Fats: A Comparison of Fatty Acids in the Promotion of Insulin Resistance, Inflammation, and Obesity. Mo. Med. 2017, 114, 303–307.
  52. Currenti, W.; Godos, J.; Alanazi, A.M.; Lanza, G.; Ferri, R.; Caraci, F.; Grosso, G.; Galvano, F.; Castellano, S. Dietary Fats and Cognitive Status in Italian Middle-Old Adults. Nutrients 2023, 15, 1429.
  53. Kim, H.J.; Zhao, J.; Walewski, J.L.; Sparrow, J.R. A High Fat Diet Fosters Elevated Bisretinoids. J. Biol. Chem. 2023, 299, 104784.
  54. Deol, P.; Kozlova, E.; Valdez, M.; Ho, C.; Yang, E.W.; Richardson, H.; Gonzalez, G.; Truong, E.; Reid, J.; Valdez, J.; et al. Dysregulation of Hypothalamic Gene Expression and the Oxytocinergic System by Soybean Oil Diets in Male Mice. Endocrinology 2020, 161, bqz044.
  55. Deol, P.; Evans, J.R.; Dhahbi, J.; Chellappa, K.; Han, D.S.; Spindler, S.; Sladek, F.M. Soybean oil is more obesogenic and diabetogenic than coconut oil and fructose in mouse: Potential role for the liver. PLoS ONE 2015, 10, e0132672.
  56. Deol, P.; Fahrmann, J.; Yang, J.; Evans, J.R.; Rizo, A.; Grapov, D.; Salemi, M.; Wanichthanarak, K.; Fiehn, O.; Phinney, B.; et al. Omega-6 and omega-3 oxylipins are implicated in soybean oil-induced obesity in mice. Sci. Rep. 2017, 7, 12488.
  57. Piñeros, A.R.; Kulkarni, A.; Gao, H.; Orr, K.S.; Glenn, L.; Huang, F.; Liu, Y.; Gannon, M.; Syed, F.; Wu, W.; et al. Proinflammatory signaling in islet β cells propagates invasion of pathogenic immune cells in autoimmune diabetes. Cell Rep. 2022, 39, 111011.
  58. Hernandez, M.L.; Sicardo, M.D.; Belaj, A.; Martínez-Rivas, J.M. The oleic/linoleic acid ratio in olive (Olea europaea Lfruit mesocarp is mainly controlled by OeFAD2-2 and OeFAD2-5 genes together with the different specificity of extraplastidial acyltransferase enzymes. Front. Plant Sci. 2021, 12, 653997.
  59. CBS News. 60 Minutes Overtime: Don’t Fall Victim to Olive Oil Fraud. Available online: (accessed on 13 April 2023).
  60. Shah, A.K.; Dhalla, N.S. Effectiveness of some vitamins in the prevention of cardiovascular disease: A narrative review. Front. Physiol. 2021, 12, 729255.
  61. Ong, D.E.; Chytil, F. Vitamin A and cancer. Vitam. Horm. 1983, 40, 105–144.
  62. Sommer, A. Vitamin A deficiency and clinical disease: An historical overview. J. Nutr. 2008, 128, 1835–1839.
  63. Cabiddu, A.; Delgadilla-Puga, C.; Decandia, M.; Molle, G. Extensive ruminant production systems and milk quality with emphasis on unsaturated fatty acids, volatile compounds, antioxidant protection degree and phenol content. Animals 2019, 9, 771.
  64. Nürnberg, K.; Wegner, J.; Ender, K. Factors influencing fat composition in muscle and adipose tissue of farm animals. Livest. Prod. Sci. 1998, 56, 145–156.
  65. Klebanov, G.I.; YuO, T.; Babenkova, I.V.; Lyubitsky, O.B.; OYu, R.; Boldyrev, A.A.; YuA, V. Effect of carnosine and its components on free-radical reactions. Membr. Cell Biol. 1998, 12, 89–99.
  66. Boldyrev, A.; Bulygina, E.; Leinsoo, T.; Carpenter, D.O. Protection of neuronal cells against reactive oxygen species by carnosine and related compounds. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 2004, 137, 81–88.
  67. Chan, K.M.; Decker, E.A. Endogenous skeletal muscle antioxidants. Crit. Rev. Food Sci. Nutr. 1994, 34, 403–426.
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to : ,
View Times: 144
Revisions: 2 times (View History)
Update Date: 25 Jul 2023